

Attorney Docket No.: ISPH-0526
Inventors: McKay et al.
Serial No.: 09/774,809
Filing Date: January 31, 2001
Page 2

In the Specification:

Please replace the paragraph beginning at page 64, line 12, with the following paragraph:

In order to evaluate the activity of potential JNK-modulating oligonucleotides, human lung carcinoma cell line A549 (American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, No. ATCC CCL-185) cells or other cell lines as indicated in the Examples, were grown and treated with oligonucleotides or control solutions as detailed below. After harvesting, cellular extracts were prepared and examined for specific JNK mRNA levels or JNK protein levels (i.e., Northern or Western assays, respectively). In all cases, "% expression" refers to the amount of JNK-specific signal in an oligonucleotide-treated cell relative to an untreated cell (or a cell treated with a control solution that lacks oligonucleotide), and "% inhibition" is calculated as

$$100\% - \% \text{Expression} = \% \text{Inhibition.}$$

Please replace the paragraph beginning at page 102, line 3, with the following paragraph:

Approximately 5×10^6 breast adenocarcinoma cells (cell line MDA-MB-231; American Type Culture Collection, 10801 University

Attorney Docket No.: ISPH-0526
Inventors: McKay et al.
Serial No.: 09/774,809
Filing Date: January 31, 2001
Page 3

11/2 Boulevard, Manassas, VA 20110-2209, No. ATCC HTB-26) were implanted subcutaneously in the right inner thigh of nude mice (n=6 for each of three sets of mice). Oligonucleotides ISIS 15346 (JNK1, SEQ ID NO:16) and 15353 (JNK2, SEQ ID NO:31) were suspended in saline and administered once daily to two sets of mice on the first day the tumor volume was about 100 mm³. A saline-only (0.9% NaCl) solution was given to a third set of animals as a control. Oligonucleotides were given by intravenous injection at a dosage of 25 mg/kg. Tumor size was measured and tumor volume was calculated on days 12, 19, 26 and 33 following tumor cell inoculation.--

In the Claims:

Please cancel claims 1-13, 15-20 and 23-27 without prejudice.

Please amend the claims as follows:

14. (amended) A method of modulating the expression of human JNK2 protein in cells or tissues comprising contacting said cells or tissues with an oligonucleotide from 8 to 30 nucleotides connected by covalent linkages, and wherein said oligonucleotide has a sequence specifically hybridizable with a nucleic acid molecule encoding human JNK2 protein and said oligonucleotide modulates the expression of said human JNK2 protein.